Accordingly, IFN-γ has been used clinically to treat a variety of malignancies.38 IFN-γ treatment is not always beneficial, and some clinical trials against melanoma pointed out that signalling context and tumour microenvironment factors could even turn IFN-γ to a pro-inflammatory and thus a carcinogenic factor.38 Nevertheless, studies agree that it could be a viable new therapeutic target for a subset of malignancies.38 The gene discussed is IFNG; the disease is neoplasm.